Research programme: anticancer therapeutics - CBT Pharmaceuticals

Drug Profile

Research programme: anticancer therapeutics - CBT Pharmaceuticals

Alternative Names: CBT-102; CBT-502; TQB-2450

Latest Information Update: 24 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CBT Pharmaceuticals
  • Developer CBT Pharmaceuticals; Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Monoclonal antibodies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Mitogen-activated protein kinase inhibitors; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Apr 2018 Pharmacodynamics data of CBT 102 from preclinical studies presented at the Annual Meeting of American Association for Cancer Research, 2018 (AACR-2018)
  • 14 Mar 2018 Chia-tai Tianqing Pharmaceutical Group plans a phase I trial of TQB 2450 for Cancer (In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in March 2018 (NCT03460457)
  • 01 Sep 2016 CBT 502 licensed to Chia Tai TianQing in China (CBT Pharmaceuticals pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top